PSI(Synonyms: Proteasome Inhibitor 1)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

PSI (Synonyms: Proteasome Inhibitor 1)

PSI (Proteasome Inhibitor 1) 是一种有效的蛋白酶体 proteasome 抑制剂。PSI 抑制原发性渗出性淋巴瘤 (PEL) 细胞的增殖。PSI具有研究卡波济氏肉瘤相关疱疹病毒 (KSHV) 感染和 KSHV 相关淋巴瘤的潜力。

PSI(Synonyms: Proteasome Inhibitor 1)

PSI Chemical Structure

CAS No. : 158442-41-2

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

PSI (Proteasome Inhibitor 1) is a potent proteasome inhibitor. PSI inhibits the proliferation of primary effusion lymphoma (PEL) cells. PSI has the potential for the research of Kaposi’s sarcoma-associated herpesvirus (KSHV) infection and KSHV-associated lymphomas[1].

体外研究
(In Vitro)

PSI (24 h) inhibits the proliferation of primary effusion lymphoma (PEL) cells at low nanomolar concentrations (CC50s of 205, 190, 22.0, 53.0 nM FOR BJAB, Ramos, BC3, BCBL1 cells, respectively)[1].
PSI (50 nM; 6 h) increases caspase-3/7 activity by 8-fold compared with control[1].
PSI (50 nM; 6 h) decreases the transcriptional activity of NF-κB by 52%[1].
PSI (1, 5 nM; 3 days) inhibits the growth of BC3 cells at a high concentration (5 nM)[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line: BC3, BCBL1, Ramos, BJAB cells
Concentration:
Incubation Time: 24 h
Result: Inhibited the proliferation of primary effusion lymphoma (PEL) cells at low nanomolar concentrations (CC50s of 205, 190, 22.0, 53.0 nM FOR BJAB, Ramos, BC3, BCBL1 cells, respectively).

Western Blot Analysis[1]

Cell Line: HBL6 cells
Concentration: 50 nM
Incubation Time: 6 h
Result: Decreased the NF-κB activity by 52%.

分子量

618.76

Formula

C32H50N4O8
CAS 号

158442-41-2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Saji C, et al. Proteasome inhibitors induce apoptosis and reduce viral replication in primary effusion lymphoma cells. Biochem Biophys Res Commun. 2011; 415(4):573-8.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

发表回复